Bristol Myers Squibb Company $BMY Stock Sold by Courier Capital LLC

Courier Capital LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 26.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,000 shares of the biopharmaceutical company’s stock after selling 9,523 shares during the period. Courier Capital LLC’s holdings in Bristol Myers Squibb were worth $1,622,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Euro Pacific Asset Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at $203,000. Sage Capital Advisors llc raised its position in shares of Bristol Myers Squibb by 0.7% during the third quarter. Sage Capital Advisors llc now owns 88,538 shares of the biopharmaceutical company’s stock worth $5,525,000 after acquiring an additional 580 shares during the last quarter. Steel Grove Capital Advisors LLC lifted its stake in shares of Bristol Myers Squibb by 2.3% during the third quarter. Steel Grove Capital Advisors LLC now owns 34,186 shares of the biopharmaceutical company’s stock valued at $2,133,000 after acquiring an additional 758 shares during the period. Sax Wealth Advisors LLC boosted its holdings in Bristol Myers Squibb by 55.5% in the third quarter. Sax Wealth Advisors LLC now owns 10,357 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 3,695 shares during the last quarter. Finally, Fragasso Financial Advisors Inc boosted its holdings in Bristol Myers Squibb by 7.8% in the third quarter. Fragasso Financial Advisors Inc now owns 4,965 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 360 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 1.5%

NYSE BMY traded down $0.85 on Tuesday, reaching $56.73. The company had a trading volume of 16,958,086 shares, compared to its average volume of 12,081,742. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The stock’s 50 day moving average is $63.99 and its 200-day moving average is $60.30. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market cap of $115.89 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 0.29 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company’s revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.80 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Insider Transactions at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: RYZ101 delivered a significant Phase 3 win. RayzeBio’s radiopharmaceutical therapy met the primary endpoint in the ACTION-1 trial, producing a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced gastroenteropancreatic neuroendocrine tumors. The result supports discussions with regulators and strengthens BMY’s $4.1 billion radiopharmaceutical strategy. Bristol Myers Squibb Announces Positive Topline Results for RYZ101
• Positive Sentiment: Admilparant showed efficacy in idiopathic pulmonary fibrosis. The ALOFT-IPF Phase 3 trial met its primary endpoint at the 60-mg twice-daily dose, with reported clinical benefits and a favorable safety profile. The drug could address a serious chronic lung disease and provide a new growth opportunity for BMY. Bristol Myers Squibb Announces ALOFT-IPF Results
• Neutral Sentiment: The stock’s valuation remains a debate. BMY has gained roughly 38% over the past year, while analysts continue to view the shares as relatively inexpensive. However, the recent rally raises questions about whether current earnings and pipeline progress fully justify the valuation.
• Negative Sentiment: Mixed admilparant data limited the market’s reaction. Only the lower dose met the trial’s primary endpoint; the higher dose failed, creating uncertainty about the drug’s optimal dose and commercial potential. This prompted reports describing the results as “confounding” and contributed to BMY shares weakening after an initial positive response. Bristol Myers Admilparant Trial Results
• Negative Sentiment: Wells Fargo lowered its price target. The firm cut its target from $65 to $60 and maintained an “equal weight” rating, signaling limited near-term upside despite the trial announcements.
• Negative Sentiment: Upcoming earnings could add pressure. Analysts expect third-quarter earnings to decline by a single-digit percentage, keeping attention on BMY’s ability to offset generic competition and future patent-related revenue losses.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on BMY shares. Raymond James Financial started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Truist Financial restated a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Finally, Guggenheim reissued a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $64.88.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.